1.22
price up icon6.09%   0.07
pre-market  Vorhandelsmarkt:  1.23   0.01   +0.82%
loading
Schlusskurs vom Vortag:
$1.15
Offen:
$1.14
24-Stunden-Volumen:
3.23M
Relative Volume:
0.74
Marktkapitalisierung:
$241.80M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-0.5755
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
+7.96%
1M Leistung:
+14.02%
6M Leistung:
-44.55%
1J Leistung:
-49.38%
1-Tages-Spanne:
Value
$1.13
$1.235
1-Wochen-Bereich:
Value
$1.10
$1.27
52-Wochen-Spanne:
Value
$0.6925
$3.94

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name
Firmenname
Esperion Therapeutics Inc
Name
Telefon
734-887-3903
Name
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Name
Mitarbeiter
304
Name
Twitter
@esperioninc
Name
Nächster Verdiensttermin
2025-03-04
Name
Neueste SEC-Einreichungen
Name
ESPR's Discussions on Twitter

Vergleichen Sie ESPR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
ESPR
Esperion Therapeutics Inc
1.22 223.97M 116.33M -209.25M -135.49M -2.12
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
151.19 68.05B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.55 46.58B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.65 43.71B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.29 18.40B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
297.89 13.23B 2.99B 1.21B 1.13B 25.06

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-18 Eingeleitet Goldman Neutral
2024-12-17 Eingeleitet Cantor Fitzgerald Overweight
2024-06-20 Herabstufung BofA Securities Neutral → Underperform
2024-01-03 Herabstufung BofA Securities Buy → Neutral
2023-11-20 Fortgesetzt JP Morgan Neutral
2023-08-01 Hochstufung Northland Capital Under Perform → Market Perform
2023-06-15 Hochstufung BofA Securities Underperform → Buy
2023-03-16 Herabstufung BofA Securities Neutral → Underperform
2023-03-16 Herabstufung Northland Capital Market Perform → Under Perform
2023-03-07 Hochstufung Credit Suisse Underperform → Neutral
2023-02-27 Fortgesetzt BofA Securities Neutral
2023-02-24 Hochstufung Jefferies Hold → Buy
2023-02-03 Hochstufung Morgan Stanley Underweight → Equal-Weight
2022-08-03 Herabstufung Credit Suisse Neutral → Underperform
2022-05-05 Hochstufung JP Morgan Underweight → Neutral
2022-03-10 Eingeleitet H.C. Wainwright Buy
2021-10-19 Herabstufung Credit Suisse Outperform → Neutral
2021-10-14 Herabstufung Morgan Stanley Equal-Weight → Underweight
2021-05-05 Herabstufung Stifel Buy → Hold
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-03-11 Eingeleitet Morgan Stanley Equal-Weight
2021-02-12 Herabstufung Jefferies Buy → Hold
2021-02-09 Herabstufung Goldman Neutral → Sell
2021-01-15 Herabstufung BofA Securities Buy → Neutral
2020-11-10 Hochstufung Credit Suisse Neutral → Outperform
2020-09-29 Fortgesetzt JP Morgan Underweight
2020-08-11 Herabstufung Credit Suisse Outperform → Neutral
2020-04-01 Fortgesetzt BofA/Merrill Buy
2020-03-17 Hochstufung Citigroup Neutral → Buy
2020-02-24 Herabstufung Northland Capital Outperform → Market Perform
2020-02-14 Herabstufung Citigroup Buy → Neutral
2019-09-16 Hochstufung Goldman Sell → Neutral
2019-05-29 Herabstufung Goldman Neutral → Sell
2019-05-06 Hochstufung BofA/Merrill Underperform → Neutral
2019-04-26 Hochstufung Goldman Sell → Neutral
2019-03-13 Hochstufung JP Morgan Underweight → Neutral
2019-01-07 Bestätigt Needham Strong Buy
2018-12-13 Eingeleitet Goldman Sell
2018-10-29 Hochstufung Northland Capital Market Perform → Outperform
2018-10-16 Eingeleitet BTIG Research Buy
2018-08-17 Hochstufung Citigroup Neutral → Buy
2018-07-11 Herabstufung Northland Capital Outperform → Market Perform
2018-05-03 Herabstufung JP Morgan Neutral → Underweight
2018-05-02 Herabstufung BofA/Merrill Buy → Underperform
Alle ansehen

Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten

pulisher
Jul 22, 2025

Is Esperion Therapeutics Inc. a good long term investmentAccelerated profit realization - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Esperion to Announce Second Quarter 2025 Financial Results on August 5, 2025 - Quiver Quantitative

Jul 22, 2025
pulisher
Jul 22, 2025

Esperion to Report Second Quarter 2025 Financial Results on August 5 - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Esperion Therapeutics Inc. stock priceUnstoppable profit momentum - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

What analysts say about Esperion Therapeutics Inc. stockFree Stock Market Return Analysis - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

Esperion Therapeutics Inc. Stock Analysis and ForecastGame-changing capital returns - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 15, 2025

How Esperion Therapeutics Inc. stock performs during market volatilityHigh Accuracy Alerts - beatles.ru

Jul 15, 2025
pulisher
Jul 09, 2025

Esperion settles litigation with Accord Healthcare - MSN

Jul 09, 2025
pulisher
Jul 08, 2025

Esperion settles litigation with Accord Healthcare (ESPR) - Seeking Alpha

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Therapeutics Settles With Accord Healthcare to Delay Nexletol Generic Version Until 2040 - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Therapeutics Secures Extended NEXLETOL Patent Protection: A Strategic Play for Market Dominance - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Settles Patent Litigation with Accord Healthcare to Protect NEXLETOL Until 2040 - Nasdaq

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Reaches Settlement Agreement with Third ANDA Filer - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Wins Major Patent Battle: NEXLETOL Gains 15+ Years Market Exclusivity in Settlement Deal - Stock Titan

Jul 08, 2025
pulisher
Jul 02, 2025

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Esperion Therapeutics, Inc. (ESPR) - ACCESS Newswire

Jul 02, 2025
pulisher
Jul 01, 2025

Esperion Appoints Craig Thompson to Board of Directors - GlobeNewswire

Jul 01, 2025
pulisher
Jul 01, 2025

Former Pfizer VP Craig Thompson Brings $700M+ Deal Experience to Esperion Board - Stock Titan

Jul 01, 2025
pulisher
Jun 27, 2025

Dyslipidemia Market is expected to reach US$ 40.33 Billion - openPR.com

Jun 27, 2025
pulisher
Jun 17, 2025

ESPR: HC Wainwright Reiterates Buy Rating with $16 Price Target - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

RFK Racing Teams Up with Esperion for the Wellness Walk at Pocono - Speedway Digest

Jun 17, 2025
pulisher
Jun 16, 2025

Esperion Therapeutics Soars 19.66% on Positive Clinical Data, Debt Restructuring - AInvest

Jun 16, 2025
pulisher
Jun 14, 2025

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics? - Seeking Alpha

Jun 14, 2025
pulisher
Jun 13, 2025

Cantor Fitzgerald reiterates Esperion stock rating, sees growth potential By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 12, 2025

ESPR Leadership to Discuss Future Strategies in Upcoming Conference Call | ESPR Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Traders Purchase High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Transcript : Esperion Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025
pulisher
Jun 07, 2025

Research Analysts Offer Predictions for ESPR Q2 Earnings - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018ESPR - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 05, 2025

Esperion at Jefferies Global Healthcare: Expanding Opportunities By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 04, 2025

Esperion at Jefferies Global Healthcare: Expanding Opportunities - Investing.com Australia

Jun 04, 2025
pulisher
Jun 03, 2025

ProShare Advisors LLC Boosts Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Millennium Management LLC Has $1.83 Million Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Esperion settles patent case with Hetero USA over cholesterol drug By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

Esperion settles patent case with Hetero USA over cholesterol drug - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion reaches settlement agreement with Hetero USA, affiliates - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion (ESPR) Reaches Settlement to Protect NEXLETOL Patents | ESPR Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion Reaches Settlement Agreement with Second ANDA - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion Secures 15-Year Market Exclusivity for NEXLETOL in Major Patent Victory - Stock Titan

Jun 02, 2025
pulisher
May 31, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Acquired by Bank of America Corp DE - Defense World

May 31, 2025
pulisher
May 31, 2025

Deutsche Bank AG Sells 1,393,852 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

May 31, 2025
pulisher
May 31, 2025

Zacks Research Has Pessimistic Outlook of ESPR Q2 Earnings - Defense World

May 31, 2025
pulisher
May 30, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Lifted by Nuveen Asset Management LLC - Defense World

May 30, 2025
pulisher
May 30, 2025

Zacks Research Has Positive Outlook of ESPR FY2027 Earnings - Defense World

May 30, 2025
pulisher
May 27, 2025

BNP Paribas Financial Markets Has $337,000 Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

May 27, 2025
pulisher
May 26, 2025

D. E. Shaw & Co. Inc. Grows Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

May 26, 2025
pulisher
May 24, 2025

Northern Trust Corp Buys 65,662 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

May 24, 2025

Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$72.34
price up icon 1.09%
$14.93
price up icon 1.70%
$9.24
price up icon 3.82%
drug_manufacturers_specialty_generic RDY
$14.41
price down icon 0.96%
$132.75
price up icon 0.70%
$297.89
price up icon 1.63%
Kapitalisierung:     |  Volumen (24h):